Suppressing PRMT1 by knocking down its expression or using pharmacological inhibitors abrogated the increases in CRC cell proliferation, migration, and invasion mediated by R251-methylated NONO, an effect that was independent of KRAS mutation status (Fig. 7). This evidence concerns the gene KRAS and colorectal carcinoma.